These anti-IL-5 treatments are effective at reducing blood eosinophils, but our data suggest that IL-13-driven pathways may be responsible for the maintenance and survival of these cells in COPD lung tissue. The gene discussed is IL5; the disease is chronic obstructive pulmonary disease.